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The aim of the study presented here was an attempt 
to answer the question posed in the title: Is the mech-
anism of nitroglycerin tolerance associated with alde-
hyde dehydrogenase (ALDH) activity? Here, we investi-
gated the effect of administration (separately or joint-
ly) of lipoic acid (LA), nitroglycerin (GTN), and disulfi-
ram (DSF; an irreversible in vivo inhibitor of all ALDH 
isozymes (including ALDH2)), on the development of 
tolerance to GTN. We also assessed the total activity 
of ALDH in the rat liver homogenates. Our data re-
vealed that not only DSF and GTN inhibited the total 
ALDH activity in the rat liver, but LA also proved to 
be an inhibitor of this enzyme. At the same time, the 
obtained results demonstrated that the GTN tolerance 
did not develop in GTN, DSF and LA jointly treated 
rats, but did develop in GTN and DSF jointly treated 
rats. This means that the ability of LA to prevent GTN 
tolerance is not associated with the total ALDH activi-
ty in the rat liver. In this context, the fact that animals 
jointly receiving GTN and DSF developed tolerance to 
GTN, and in animals that in addition to GTN and DSF 
also received LA such tolerance did not develop, is – 
in our opinion – a sufficient premise to conclude that 
the nitrate tolerance certainly is not caused by a de-
crease in the activity of any of the ALDH isoenzymes 
present in the rat liver, including ALDH2. However, 
many questions still await an answer, including the 
basic one: What is the mechanism of tolerance to ni-
troglycerin?
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INTRODUCTION
Since 1879, when Murrell discovered the antianginal 
effect of a 1% solution of oral nitroglycerin (glyceryl 
trinitrate; GTN), it became the most popular drug in 
everyday medical practice. It is used in the ambulance, 
outpatient and inpatient care. Its usefulness in ending 
sudden angina in documented coronary artery disease is 
unquestioned (Kosmulski et al., 2019).
GTN is thought to be converted in the vasculature 
into nitric oxide (NO) or some NO adjunct which ac-
tivates the soluble guanylate cyclase (sGC) and subse-
quently elevates the cGMP level, resulting in vasodilata-
tion (Murad, 2004). However, long-term GTN therapy 
causes development of nitrate tolerance, which is defined 
as a reduced response to treatment with organic nitrates, 
or the need to increase dosages to maintain the effects,. 
PubMed lists more than 15000 publications on GTN. 
It is worth to recall that the first work describing the 
phenomenon of GTN tolerance was published in 1898 
(Laws, 1898). However, the molecular mechanism of 
GTN biotransformation has remained a mystery and it is 
not well understood why tolerance manifests over time.
Aldehyde dehydrogenase (ALDH, EC 1.2.1.3) is a 
polymorphic enzyme responsible for many life processes 
(cell division, differentiation, proliferation, response to 
oxidative stress and cellular homeostasis) and oxidation 
of endogenous and exogenous aldehydes to their respec-
tive carboxylic acids (Christy & Doss, 2014; Vasiliou et 
al., 2000). In mammals, the ALDH isozymes are tradi-
tionally divided into three classes: class 1 (ALDH1; cy-
tosolic), class 2 (ALDH2; mitochondrial), and class 3 
(ALDH3; such as those expressed in tumors, stomach, 
and cornea). ALDH1 and ALDH2 are the most impor-
tant enzymes for aldehyde oxidation. These enzymes are 
found in many tissues of the body, but occur in the liver 
at the highest concentration. Mammalian liver class 1 
and class 2 ALDH isoforms were purified in the 1970s, 
and have been used extensively as models for testing 
their kinetic and structural properties. It is now known 
that the kinetic properties and subcellular distribution of 
the major mitochondrial and cytosolic ALDH isozymes 
isolated from different species are similar. Mitochondrial 
(low-Km) ALDH2 is the major enzyme oxidizing ethanol-
derived acetaldehyde, both in humans and rats (Moon et 
al., 2007).
Taken together, in rodents, both ALDH1 and ALDH2 
are involved in the acetaldehyde metabolism because 
ALDH1 isozymes also exhibit a relatively low Km values 
(11–18 μM range) for acetaldehyde; in humans, ALDH2 
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plays a major role in acetaldehyde detoxification follow-
ing ethanol metabolism in vivo, since it has a very low 
Km value (≤1.0 μM range) for acetaldehyde (Klyosov et 
al., 1996).
In 2002, Chen and others (Chen et al., 2002) dem-
onstrated in vitro and in vivo that ALDH2 catalyzes for-
mation of 1,2-glyceryl dinitrate (1,2-GDN) and nitrite 
from low concentrations of GTN. The reaction required 
DTT (dithiothreitol) or 2-mercaptoethanol as reduct-
ants, and was stimulated by the ALDH cofactor NAD. 
These studies have also indicated that during this reac-
tion ALDH2 is oxidatively inhibited by GTN, causing 
down-regulation of this enzyme which is associated with 
GTN tolerance (Chen et al., 2002). By using an in vivo 
model of nitrate tolerance, DiFabio and others (DiFabio 
et al., 2003) found that inhibitors of ALDH2 caused a 
similar shift in the relaxation responses of tolerant and 
nontolerant aortas. In 2005, Kollau et al. indicated that 
ALDH2 contributed to GTN bioactivation in the blood 
vessels and rat liver mitochondria, but it was not the 
only mammalian enzyme catalyzing this process (Kollau 
et al., 2005).
In 2007, Wenzeland others (Wenzel et al., 2007) re-
ported that the activity of ALDH2 (oxidatively inhibited 
by GTN) was restored in vitro by dithiol compounds, 
such as the dithiotreitol (DTT) and dihydrolipoic acid 
(DHLA, 6,8-dimercapto-octanoic acid) (Wenzel et al., 
2007). On the other hand, in vivo experiments indicated 
that treatment of rats with lipoic acid (LA, 1,2-ditiolano-
3-pentanoic acid) in combination with and GTN, did 
not provide any protection against GTN-induced ALDH 
inhibition (it is worth mentioning that DHLA is formed 
in the body by LA reduction; Bilska-Wilkosz et al., 2016).
Beretta and others (Beretta et al., 2008) demonstrated 
in vitro that not only ALDH2, but also ALDH1 could 
convert GTN into significant amounts of NO. In 2011, 
experiments in the rat liver homogenates confirmed that 
the cytoplasmic isoform, i.e. ALDH1, was also capable 
of reducing GTN to biologically active NO (Tsou et al., 
2011). Axton and others (Axton et al., 2018) indicated 
that xanthine oxidase (XO; EC 1.17.3.2) was a critical 
enzyme for metabolic bio-activation of GTN to NO.
The discourse continues, and these problems have not 
been resolved yet.
Thus, as pointed out in the title, the study presented 
here is a modest contribution to the almost two dec-
ades-long discussion on this topic. The aim of this study 
is an attempt to answer the question: Is the mechanism 
of nitroglycerin tolerance associated with ALDH activ-
ity? Here, we investigated the effect of administering LA, 
GTN and an inhibitor of all ALDH isozymes - disulfi-
ram (DSF), on the development of tolerance to GTN. 
We also assessed the total activity of ALDH in the rat 
liver homogenates.
MATERIALS AND METHODS
Animals. All procedures were performed according 
to the Animal Use and Care Committee Guidelines and 
were approved by the Ethical Committee on Animal 
Testing at the Jagiellonian University, Kraków, Poland 
(registration number 106/2009 and ZI/UJ/403/2007).
The experiments were carried out on male Wistar rats 
(180–250 g). Animals were housed in a room in plastic 
cages at a constant temperature of 20±2°C, with natural 
light–dark cycle. They had free access to standard pellet 
diet and water.
In experiment A, we measured the systolic and dias-
tolic blood pressure in all animals before GTN adminis-
tration into the caudal vein, and during 20 min thereaf-
ter. GTN tolerance was confirmed when GTN adminis-
tered on the 5th day did not decrease the arterial blood 
pressure vs. control arterial blood pressure measured be-
fore GTN administration iv. The animals were randomly 
divided into seven groups of 8 animals each. The groups 
were treated as follows:
group 1: 0.9% NaCl, sc, 0.6 ml, for 4 days, on the 5th 
day GTN at a dose of 150 μg/kg, iv (control group);
group 2: DSF at a dose of 150 mg/kg, ip, daily di-
vided into two doses, for 4 days, on the 5th day GTN at 
a dose of 150 μg/kg, iv;
group 3: GTN at a dose of 30 mg/kg, sc, daily di-
vided into three doses, for 4 days, on the 5th day GTN 
at a dose of 150 μg/kg, iv;
group 4: GTN at a dose of 30 mg/kg, sc, daily divid-
ed into three doses, for 4 days + DSF for 4 days, a dose 
of 150 mg/kg, ip, divided into two doses, on the 5th day 
GTN at a dose of 150 μg/kg, iv (GTN-tolerance group);
group 5: LA at a dose of 100 mg/kg, ip, divided into 
two doses, for 4 days + DSF for 4 days at a dose of 150 
mg/kg ip, divided into two doses, on the 5th day GTN 
at a dose of 150 μg/kg, iv;
group 6: GTN at a dose of 30 mg/kg sc, daily divided 
into three doses for 4 days + DSF for 4 days at a dose 
of 150 mg/kg, ip, divided into two doses + LA for 4 
days at a dose of 100 mg/kg, ip, divided into two doses, 
on the 5th day GTN at a dose of 150 μg/kg, iv;
group 7: LA at a dose of 100 mg/kg ip, daily divided 
into two doses, for 4 days, on the 5th day GTN at a 
dose of 150 μg/kg, iv.
Blood pressure measurement. The rats were an-
esthetized with thiopental (70 mg/kg) ip injection. The 
left carotid artery was cannulated with polyethylene 
tubing filled with a heparin solution in saline to facili-
tate pressure measurements using the Datamax appara-
tus (Columbus Instruments, Ohio). Blood pressure was 
measured before GTN (150 μg/kg; iv.) administration 
into the caudal vein and during 20 min thereafter. Sub-
sequently, animals were sacrificed by cervical disloca-
tion and the livers were excised, washed in 0.9% NaCl, 
placed in liquid nitrogen and stored at –80oC until the 
ALDH activity test was performed.
Aldehyde dehydrogenase activity. The frozen livers 
were weighed and homogenates were prepared by ho-
mogenization of 1 g of the tissue in 4 ml of 0.1 M phos-
phate buffer, pH 7.4, using an IKA-ULTRA-TURRAX 
T8 homogenizer. Total aldehyde dehydrogenase (ALDH) 
activity was measured as NADH formation from NAD+ 
in the presence of propionaldehyde by monitoring an in-
crease in the absorbance at 340 nm, using a modified 
protocol published earlier (Loomis & Brien, 1983; Tott-
mar et al., 1973).
The assay mixture (1 ml) contained 50 mM sodium 
pyrophosphate buffer (pH 8.2), 1 mM NAD, 1 mM 
EDTA, 1 mM 4-methylpyrazole (to inhibit alcohol de-
hydrogenase, ADH), 2 μM rotenone (to inhibit NADH 
consumption by complex I of the electron transfer 
chain). The reaction was initiated by addition of 10 mM 
propionaldehyde to the cuvette, and absorbance change 
was monitored for 3 min at 37oC to calculate the rate of 
NADH production.
ALDH activity was calculated by using the mo-
lar extinction coefficient of reduced NAD(P) of 
6.22 mM–1cm–1 at 340 nm. Enzyme-specific activity was 
expressed as nmol NADH min–1 mg–1 protein.
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Protein content. Protein content was assayed by the 
Lowry and others (Lowry et al., 1951) method which is 
based on the reaction of peptide bonds and aromatic 
amino acid residues of proteins with the Folin-Ciocal-
teau reagent (a mixture of phosphotungustic acid and 
phosphomolibdenic acid) in an alkaline environment, in 
the presence of cupric ions. Copper (II) ions bound to 
the protein tyrosine and tryptophan residues reduce the 
above acids to oxides.
Absorbance was measured at 500 nm. A 1% solution 
of bovine albumin was used to prepare a standard curve.
Drugs and compounds. Nitroglycerin was purchased 
from LEK S.A. and Pliva Kraków S.A. (Poland). Lipoic 
acid was a gift from Hexal®AG, (Holzkirchen, Germany). 
Disulfiram was purchased from Sigma-Aldrich Chemi-
cal Company (Poznań, Poland). Thiopental sodium was 
obtained from HEFA-Frenon Arzneimittel (Germany). 
The Folin–Ciocalteau reagent, β-nicotinamide adenine 
dinucleotide tetrasodium salt (NAD), EDTA, rotenone, 
propionaldehyde, and 4-methylpyrazole were provided by 
Sigma-Aldrich Chemical Company (Poznań, Poland). All 
the other reagents were of analytical grade and were ob-
tained from Polish Chemical Reagent Company (POCh, 
Gliwice, Poland).
Statistical analysis. All statistical calculations were 
carried out with the STATISTICA 8.0 computer pro-
gram. The mean and standard deviation of the mean 
were calculated for each group. Normal distribution was 
verified with the Kołmogorow-Smirnow test. Data were 
analyzed by the Student’s t-test. Differences were consid-
ered as statistically significant when p<0.05.
RESULTS AND DISCUSSION
Our data revealed that not only DSF and GTN in-
hibited the total ALDH activity in the rat liver, but LA 
also proved to be an inhibitor of this enzyme (Table 1). 
As for DSF, it is obvious. In case of GTN, this is con-
firmed by literature data. GTN-induced inhibition of the 
ALDH activity was already noticed by Towell and oth-
ers (Towell et al., 1985) in 1985. Notably, this was done 
with ALDH found in erythrocytes, which is a cytoplas-
mic isoform of this enzyme. It is also known that GTN 
potently inhibited both, purified yeast ALDH and GTN-
treated rats’ ALDH2 from isolated cardiac mitochondria 
in vivo (Wenzel et al., 2007). It was also demonstrated 
that GTN inhibited ALDH2 activity in circulating white 
blood cells (WBC) of healthy volunteers (Wenzel et al., 
2009). Beretta and others (Beretta et al., 2008) showed 
that GTN blocked ALDH2 activity in isolated rat liver 
mitochondria, as well as activity of recombinant human 
ALDH2.
At the same time, the study presented here demon-
strated that DSF treatment alone (without GTN) and 
GTN treatment alone (without DSF) did not cause tol-
erance after 4 days of GTN administration, since the 
animals responded to intravenous administration of 
GTN on day 5 with a significant drop in blood pressure 
(Fig. I-2 and I-3, respectively). However, the obtained 
results showed that tolerance developed in the group 
jointly treated with GTN and DSF, in which intrave-
nous administration of GTN on day 5 did not elicit any 
significant drop in blood pressure (Fig. I-4). Our earlier 
studies demonstrated that GTN treatment alone (without 
DSF) induced tolerance after 8 days (Dudek et al., 2008). 
Results presented here also demonstrate that DSF accel-
erated GTN tolerance in rats, but it did not cause toler-
ance per se, even though it inhibited the ALDH activity. 
At the same time, our data revealed that tolerance did 
not develop in animals jointly treated with GTN, DSF 
and LA, although LA was not only unable to restore 
the ALDH activity inhibited by DSF, but on the con-
trary, it acted as an inhibitor of this enzyme (Fig. I-6; 
Table 1). This is confirmed by our earlier studies which 
concentrated on the protective effect of LA in rats with 
acute intoxication due to the combined administration of 
ethanol and DSF (Bilska-Wilkosz et al., 2019b). Taken 
together, our data indicate that the ability of LA to pre-
vent GTN tolerance is not associated with ALDH activ-
ity in the rat liver.
Results obtained by many researchers seem to support 
the thesis that tolerance to GTN is not affiliated with 
the activity of ALDH2. Li and others (Li et al., 2006) 
investigated the relationship between interindividual vari-
ability in the efficacy of sublingual GTN and ALDH2 
polymorphism in a Chinese population. The studies 
showed that among the population showing normal 
ALDH-2 – genotype (Glu504 homozygotes), GTN was 
efficacious in 85.1% persons, while among those carry-
ing ALDH-2*1/2 (Glu504Lys heterozygotes) or ALDH-
2*2/2 (Lys504 homozygotes) genotype, only 57% reacted 
in this way. The authors suggested that history of alco-
hol intolerance can be a simple marker of a potential 
GTN tolerance (Li et al., 2006). However, these results 
can be discerned in a different way, namely: why did 7 
persons (14.9%) with normal ALDH-2 activity react to 
GTN abnormally and why did 19 persons (42.4%) with 
genetically determined low activity of ALDH-2 react to 
GTN normally? Moreover, a literature survey failed to 
find a reference documenting altered therapeutic effects 
of nitrates in an Asian population. Chen et al. showed 
that ALDH-2-deficient mice (ALDH-2 -/-) did not devel-
op GTN tolerance at substantially higher concentrations 
of GTN (Chen et al., 2005). Mayer and Beretta (Mayer 
& Beretta, 2008) had stressed that the involvement of 
ALDH-2 inactivation in vascular tolerance to GTN was 
controversial.
In vitro studies with the use of human ALDH2 and 
isolated animal tissues (blood vessels, liver and heart) 
provide evidence for an efficient and potent ALDH2-
independent pathway of GTN bio-activation in the por-
cine and bovine coronary arteries. The authors suggested 
that if this pathway was present in human blood vessels, 
it might contribute to the therapeutic effect of organic 
nitrates that are not metabolized by ALDH2 (Neubauer 
et al., 2015). A recent study by D’Souza et al. demon-
strated that during development of GTN tolerance in 
rats and during tolerance reversal, changes in the GTN-
Table 1. The effect of various combinations of disulfiram (DSF), 
nitroglycerin (GTN), and lipoic acid (LA) on the total activity of 
aldehyde dehydrogenase (ALDH) in the rat liver.
Treatment
Activity of ALDH in the 
rat liver
(mIU/mg protein)
Control (group 1) 46.09±9.90
DSF (group 2) 24.30aaa±7.70
GTN (group 3) 29.00aaa±8.45
GTN + DSF (group 4; tolerant group) 23.48aaa±4.37
LA and DSF (group 5) 27.40aaa±5.15
GTN + DSF + LA (group 6) 23.60aaa±6.64
LA (group 7) 30.59aaa±1.44
Data are shown as the mean ± standard deviation (S.D.) of 8 animals 
per group; aaap<0.001 vs. group receiving 0.9% NaCl (control group).
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Figure I. The effect of various combinations of disulfiram (DSF), 
nitroglycerin (GTN), and lipoic acid (LA) on the systolic (A; blue 
line) and diastolic (B; red line) blood pressure in rats.
1. (A) systolic and (B) diastolic blood pressure ± S.D. after intrave-
nous administration of GTN (150 μg/kg, iv) on the 5th day to rats 
which received 0.6 ml 0.9%NaCl, sc, for 4 days (group 1 – control 
group). *significant vs. control arterial blood pressure measured 
before GTN administration, iv. ****p<0.01; ****p<0.001; non-tolerant 
rats; 2. (A) systolic and (B) diastolic blood pressure ± S.D. after in-
travenous administration of GTN (150 μg/kg, iv) on the 5th day 
to rats which were injected DSF at 150 mg/kg daily, divided into 
two doses, sc, for 4 days (group 2). *significant vs. control arterial 
blood pressure measured before GTN administration, iv. *p<0.05; 
***p<0.01; non-tolerant rats; 3. (A) systolic and (B) diastolic blood 
pressure ± S.D. after intravenous administration of GTN (150 μg/
kg, iv) on the 5th day to rats which were injected GTN at 30 mg/
kg daily, divided into three doses, sc, for 4 days (group 3). *sig-
nificant vs. control arterial blood pressure measured before GTN 
administration, iv. ****p<0.001; non-tolerant rats; 4. (A) systolic and 
(B) diastolic blood pressure ± S.D. after intravenous administration 
of GTN (150 μg/kg, iv) on the 5th day to rats which were injected 
GTN at 30 mg/kg daily, divided into three doses, sc, for 4 days 
+ DSF at 150 mg/kg daily, divided into two doses, ip, for 4 days 
(group 4). *significant vs. control arterial blood pressure meas-
ured before GTN administration, iv. No significant differences were 
found (*p<0.05; **p<0.02; ***p<0.01, ****p<0.001); tolerant rats; 5. (A) 
systolic and (B) diastolic blood pressure ± S.D. after intravenous 
administration of GTN (150 μg/kg, iv) on the 5th day to rats which 
were injected LA at 100 mg/kg daily, divided into two doses, ip, 
for 4 days + DSF at 150 mg/kg daily, divided into two doses, ip, 
for 4 days (group 5). *significant vs. control arterial blood pres-
sure measured before GTN administration, iv.**p<0.02; ****p<0.001; 
non-tolerant rats; 6. (A) systolic and (B) diastolic blood pressure 
± S.D. after intravenous administration of GTN (150 μg/kg, iv) on 
the 5th day to rats which were injected GTN at 30 mg/kg daily, 
divided into three doses, sc, for 4 days + DSF at 150 mg/kg daily, 
divided into two doses, ip, for 4 days + LA at 100 mg/kg daily, di-
vided into two doses, ip, for 4 days (group 6). *significant vs. con-
trol arterial blood pressure measured before GTN administration, 
iv. ***p<0.01; ****p<0.001; non-tolerant rats; 7. (A) systolic and (B) 
diastolic blood pressure ± S.D. after intravenous administration of 
GTN (150 μg/kg, iv) on the 5th day to rats which were injected LA 
at 100 mg/kg daily, divided into two doses, ip, for 4 days (group 
6). *significant vs. control arterial blood pressure measured before 
GTN administration, iv. ***p<0.01; ****p<0.001; non-tolerant rats.
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mediated vasodilator responses of several types of blood 
vessels (aorta, vena cava, femoral artery and femoral 
vein) and in vascular GTN biotransformation did not 
correlate with changes in the ALDH activity or ALDH2 
protein expression. The authors suggested that factors 
other than impaired ALDH2-mediated GTN bio-activa-
tion contributed to the GTN tolerance (D’Souza et al., 
2011).
It seems necessary to add at this point that our stud-
ies regarding ALDH activity were conducted on rat liver 
homogenates, prepared in such a way that mitochondria 
were not destroyed during their preparation. It means 
that we measured the total ALDH activity in these sam-
ples. Is this fact such a serious limitation of this research 
that the conclusions are unreliable? We hope that it is 
not. We designed our research to achieve the intend-
ed goal in as straightforward way as possible. That is 
why we decided to use the inhibitor of all ALDH iso-
zymes, i.e. DSF, whose action is irreversible in vivo, and 
restoration of activity of all ALDH isozymes (including 
ALDH2), is only dependent on de novo protein synthesis, 
in contrast to in vitro conditions, where the mechanism 
of action of this inhibitor is completely different from 
the one in vivo (Bilska-Wilkosz et al., 2019a; Kitson, 1975; 
Shen et al., 2000; Vallari & Pietruszko, 1982).
Therefore, we conducted in vivo studies assuming that 
if ALDH is involved in GTN metabolism, tolerance 
should develop earlier in rats treated with GTN and 
DSF in combination, when compared to GTN – only 
treated animals (without DSF). We also expected toler-
ance to develop in animals treated with GTN, DSF and 
LA in combination, since there is currently no drug that 
would restore the activity of all ALDH isozymes in vivo, 
including ALDH2, when inhibited by DSF. In this case, 
however, there was no tolerance. Thus, LA is not able 
to restore the activity of any of the ALDH isoenzymes, 
including ALDH2, and yet counteracts the phenomenon 
of tolerance. This means that the anti-tolerance activity 
of LA is not associated with any ALDH isoenzyme, in-
cluding ALDH2.
Finally, the fact that animals jointly receiving GTN 
and DSF developed tolerance to GTN, and animals that 
in addition to GTN and DSF also received LA did not 
develop such a tolerance, in our opinion is a sufficient 
premise to conclude that the nitrate tolerance certain-
ly is not caused by a decrease in the activity of any of 
the ALDH isoenzymes present in the rat liver, including 
ALDH2. However, many questions still await an answer, 
including this basic one: What is the mechanism of tol-
erance to nitroglycerin?
Therefore, the discourse still continues.
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